CA2343133A1 - Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities - Google Patents

Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities Download PDF

Info

Publication number
CA2343133A1
CA2343133A1 CA002343133A CA2343133A CA2343133A1 CA 2343133 A1 CA2343133 A1 CA 2343133A1 CA 002343133 A CA002343133 A CA 002343133A CA 2343133 A CA2343133 A CA 2343133A CA 2343133 A1 CA2343133 A1 CA 2343133A1
Authority
CA
Canada
Prior art keywords
tumor
squalamine
treatment procedure
treatment
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002343133A
Other languages
English (en)
French (fr)
Inventor
Michael Zasloff
Jon Williams
Mitchell H. Sokoloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genaera Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2343133A1 publication Critical patent/CA2343133A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002343133A 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities Abandoned CA2343133A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15072498A 1998-09-10 1998-09-10
US09/150,724 1998-09-10
PCT/US1999/020645 WO2000015176A2 (en) 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities

Publications (1)

Publication Number Publication Date
CA2343133A1 true CA2343133A1 (en) 2000-03-23

Family

ID=22535747

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002343133A Abandoned CA2343133A1 (en) 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities

Country Status (5)

Country Link
EP (1) EP1119361A4 (https=)
JP (1) JP2002524481A (https=)
AU (1) AU757649B2 (https=)
CA (1) CA2343133A1 (https=)
WO (1) WO2000015176A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
JPS6133121A (ja) * 1984-07-25 1986-02-17 Nissei Marine Kogyo Kk 制癌剤
DE69412596T2 (de) * 1993-03-10 1999-03-04 Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
DE19606355A1 (de) * 1996-02-12 1997-08-14 Schering Ag Kontrazeptive Freisetzungssysteme mit antiviraler und/oder antibakterieller Wirkung
ES2201296T3 (es) * 1996-04-26 2004-03-16 Genaera Corporation Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.

Also Published As

Publication number Publication date
WO2000015176A2 (en) 2000-03-23
WO2000015176A3 (en) 2000-07-20
EP1119361A4 (en) 2006-10-04
EP1119361A2 (en) 2001-08-01
AU6496299A (en) 2000-04-03
AU757649B2 (en) 2003-02-27
JP2002524481A (ja) 2002-08-06

Similar Documents

Publication Publication Date Title
US6596712B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
AU735884B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents
Douglas et al. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670.
DE69824750T2 (de) Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
EP3797770B1 (en) Softgel capsule comprising apalutamide
EP0415623A2 (en) Toremifene or demethyltoremifene as hydroxytoremifene for the reversal of multidrug restistance of cancer cells against cytotoxic drugs
KR20160078987A (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
CN105792845A (zh) 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
US20120214758A1 (en) Tyrosine kinase receptor antagonists and methods of treatment for pancreatic cancer
US20260027176A1 (en) Leuprolide acetate compositions and methods of using the same to treat breast cancer
Li et al. Preparation of microspheres encapsulating sorafenib and catalase and their application in rabbit VX2 liver tumor
Patel et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors
Cheng et al. A novel small molecule inhibits tumor growth and synergizes effects of enzalutamide on prostate cancer
Xue et al. Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma
AU2005308539A1 (en) Method and composition for enhancing anti-angiogenic therapy
AU757649B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
WO2007065016A2 (en) Methods and compositions to improve activity and reduce toxicity of stents
Wolf et al. Nitroglycerin decreases medial smooth muscle cell proliferation after arterial balloon injury
JP2002524481A5 (https=)
CN116492342B (zh) 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用
Yuan et al. Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV
Hussain et al. P115 A phase 2 multicenter study of the investigational single agent orteronel (ortl, TAK-700) in nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA)
Moore 13: Chemotherapy in Hormone Refractory Prostate Cancer
HK40046839A (en) Androgen receptor modulator and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead